SCHEMBL3365349

SCHEMBL3365349

O=C1NC(=O)C(=Cc2ccc(-c3cccc(C(=O)O)c3)o2)N1

nearest known ligand 0.79

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GSK3A P49840 3/20 0.79
GSK3B P49841 3/20 0.79
PIK3CG P48736 3/20 0.65
PIM1 P11309 1/20 0.63
POLB P06746 6/20 0.61
TDP1 Q9NUW8 4/20 0.61
ALDH1A1 P00352 3/20 0.61
KDM4E B2RXH2 3/20 0.61
L3MBTL1 Q9Y468 3/20 0.61
MEN1 O00255 4/20 0.58
KMT2A Q03164 4/20 0.58
GFER P55789 1/20 0.58
CTDSP1 Q9GZU7 1/20 0.58
MAPT P10636 5/20 0.54
RECQL P46063 4/20 0.54
MCL1 Q07820 4/20 0.54
KEAP1 Q14145 1/20 0.54
NFE2L2 Q16236 1/20 0.54
PSMD14 O00487 1/20 0.54
MMP2 P08253 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12990771 1.00 GSK3A (0.79) GSK3AGSK3BPIK3CGPIM1POLB
SCHEMBL3365346 1.00 GSK3A (0.79) GSK3AGSK3BPIK3CGPIM1POLB
SCHEMBL5143164 0.88 GSK3A (1.00) GSK3AGSK3BPIK3CGPIM1POLB
SCHEMBL5143166 0.88 GSK3A (1.00) GSK3AGSK3BPIK3CGPIM1POLB
SCHEMBL3362480 0.85 GSK3A (0.77) GSK3AGSK3BPOLBTDP1ALDH1A1
SCHEMBL3362481 0.85 GSK3A (0.77) GSK3AGSK3BPOLBTDP1ALDH1A1
SCHEMBL12990390 0.85 GSK3A (0.77) GSK3AGSK3BPOLBTDP1ALDH1A1
SCHEMBL13587005 0.80 GSK3A (0.81) GSK3AGSK3BPIK3CGPIM1POLB
SCHEMBL5143410 0.79 PPM1G (0.62) GSK3AGSK3BPIK3CGPOLBTDP1
SCHEMBL5143032 0.79 POLB (0.65) GSK3AGSK3BPIK3CGPOLBTDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100331315-A1 RHODANINES AND RELATED HETEROCYCLES AS KINASE INHIBITORS SENHWA BIOSCIENCES, INC. (TW) 2010-12-30 US disclosed
WO-2010148351-A1 RHODANINES AND RELATED HETEROCYCLES AS KINASE INHIBITORS CYLENE PHARMACEUTICALS, INC. (US) 2010-12-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100331315-A1 RHODANINES AND RELATED HETEROCYCLES AS KINASE INHIBITORS PIM2, PIM1, CDK2 GSK3A 412/4885GSK3B 375/4885PIK3CG 456/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.